IMUNON (IMNN) announced new safety and immunogenicity data from ongoing analyses of results from the Company’s first Phase 1 proof-of-concept ...

(NASDAQ: IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapy and evaluating an adaptation of the platform’s potential as a next-generation vaccine, today ...

Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® technology IMNN-101 induced 2- to 4-fold increase in neutralizing ...

Visby Medicaltm announced today that it has received 510(k) clearance and was granted a CLIA waiver from the U.S. Food and Drug Administration (FDA) for its point-of-care respiratory health test.

Tixagevimab-cilgavimab reduced risk for severe COVID-19 progression in patients with hematologic malignancies on anti-CD20 therapy during the early Omicron era.